Search research articles
Contact Us
Filters
Showing results (541-550 of 1,034) with videos related to
Page
of 104
Sort By:
Food Additives and Contaminants
|
January 26, 2005
Review of the toxicology, human exposure and safety assessment for bisphenol A diglycidylether (BADGE)
A Poole, P van Herwijnen, H Weideli, et al.
Journal of the American College of Cardiology
|
January 1, 1990
Pulmonary artery pressure changes during exercise and daily activities in chronic heart failure
J S Gibbs, J Keegan, C Wright, et al.
British Heart Journal
|
July 1, 1977
Haemodynamic effects of salbutamol and nitroprusside after cardiac surgery
P A Poole-Wilson, G Lewis, T Angerpointer, et al.
Journal of Chemical Information and Modeling
|
April 22, 2025
Computational Strategies for Broad Spectrum Venom Phospholipase A<sub>2</sub> Inhibitors
David A Poole, Laura-Oana Albulescu, Jeroen Kool, et al.
Circulation
|
June 1, 1996
Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist
S Kaddoura, J D Firth, K R Boheler, et al.
The Veterinary Record
|
July 24, 2001
Systemic bioavailability of erythromycin in cattle when applied by footbath
B J Hartog, S H Tap, H J Pouw, et al.
European Journal of Pharmacology
|
February 11, 1992
Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro
C W Jiang, P M Sarrel, D C Lindsay, et al.
Postgraduate Medical Journal
|
February 1, 1995
ACE inhibitors in heart failure. What dose?
J G Cleland, W N Hubbard, J Pittard, et al.
Journal of Bacteriology
|
February 1, 1987
Effect of growth phase on phospholipid biosynthesis in Saccharomyces cerevisiae
M J Homann, M A Poole, P M Gaynor, et al.
Cardiology
|
November 3, 2007
Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials
Richard M Lewis, David J Gordon, Philip A Poole-Wilson, et al.
Page
of 104
Search research articles
Search
Showing results (541-550 of 1,034) with videos related to
Sort By:
Page
of 104
Food Additives and Contaminants
|
January 26, 2005
Review of the toxicology, human exposure and safety assessment for bisphenol A diglycidylether (BADGE)
A Poole, P van Herwijnen, H Weideli, et al.
Journal of the American College of Cardiology
|
January 1, 1990
Pulmonary artery pressure changes during exercise and daily activities in chronic heart failure
J S Gibbs, J Keegan, C Wright, et al.
British Heart Journal
|
July 1, 1977
Haemodynamic effects of salbutamol and nitroprusside after cardiac surgery
P A Poole-Wilson, G Lewis, T Angerpointer, et al.
Journal of Chemical Information and Modeling
|
April 22, 2025
Computational Strategies for Broad Spectrum Venom Phospholipase A<sub>2</sub> Inhibitors
David A Poole, Laura-Oana Albulescu, Jeroen Kool, et al.
Circulation
|
June 1, 1996
Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist
S Kaddoura, J D Firth, K R Boheler, et al.
The Veterinary Record
|
July 24, 2001
Systemic bioavailability of erythromycin in cattle when applied by footbath
B J Hartog, S H Tap, H J Pouw, et al.
European Journal of Pharmacology
|
February 11, 1992
Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro
C W Jiang, P M Sarrel, D C Lindsay, et al.
Postgraduate Medical Journal
|
February 1, 1995
ACE inhibitors in heart failure. What dose?
J G Cleland, W N Hubbard, J Pittard, et al.
Journal of Bacteriology
|
February 1, 1987
Effect of growth phase on phospholipid biosynthesis in Saccharomyces cerevisiae
M J Homann, M A Poole, P M Gaynor, et al.
Cardiology
|
November 3, 2007
Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials
Richard M Lewis, David J Gordon, Philip A Poole-Wilson, et al.
Page
of 104